Health Care Stocks, News & Tips on the ASX

The Australian Health Care sector represents some of the country’s most successful companies, with fields ranging from pharmaceuticals, biotech, medical practices, pathology operators, and medical devices.

Many health care companies on the Australian Stock Exchange are leaders in their fields. It includes a whole host of dominating blue chip companies such as Cochlear, CSL, and Resmed.

On the small cap end of the market, you’ll find relatively new companies. They carry significantly more risk since there are inherent risks associated with researching, developing, and commercialising their product or service.

If you’re looking for more information, insider tips, professional analyses on up-to-date news on health care stocks, browse below for our Australian Stock Report resources.

  • Share to buy: Nanosonics (NAN)

    image002

    December quarter sales were up 41% on the prior quarter, as North American direct sales gained momentum.

    The company's move into the US market seems to be paying off, with gross margins improving significantly.

    The next driver of share price could be publication of decontamination guidelines in the UK and Scotland favourable to Nanosonic products.

    Technically, the stock remains strong and has broken out to fresh all-time highs recently on rising volumes.

    VIEW ARTICLE
  • Share to buy – Ramsay Healthcare (RHC)

    image003

    Company Snapshot:

    • Market cap: $12.01 Billion
    • Recent share price: $59.9
    • Cash/debt: $315.86 million/$3.17B
    • Trailing P/E: 32.64

    Ramsay Healthcare is the largest private hospital operator in Australia and one of the top five hospital companies in the world. It has a presence in the UK, France, Indonesia and Malaysia. In Nov 2015, they inked a joint venture agreement with one of China's leading medical universities to build a number of new private hospitals in China's Pearl River Delta thus expanding its reach further.

    RHC has a strong competitive advantage, which it has leveraged to grow its business. Key features include;

    • Guaranteed demand given the growing ageing populations on a global scale 
    • Pricing power over its customers, insurers and governments, which often have no alternative but to use Ramsay’s services.
    • Buying and building hospitals is very expensive and this is a major deterrent to other companies looking to enter the market.
    • Ramsay has also proven to be very astute at building new beds at just the right pace to grow earnings without increasing supply beyond demand. 
    • Ramsay delivered solid growth in FY15 with revenues, core earnings per share and full year dividends increasing by 49.8%, 20% and 18.8% respectively.
    • Management has provided guidance of 12-14% earnings per share growth in FY16 barring any unforeseen circumstances.
     

    VIEW ARTICLE
  • Share to buy – NIB Holdings Limited (NHF)

    image001

     

    Company Snapshot:

    • Market cap: $1.48 Billion
    • Recent share price: $3.38
    • Cash/debt: $58.81 million/$63.89Million
    • Trailing P/E: 19.54

    NIB health funds is one of Australia’s largest health insurers, providing health and medical cover to more than 1.1 million Australian and New Zealand residents

    Private Health insurers are a segment of the market worth watching over the coming 12 months.

    Both Medibank Private and NIB have become increasingly vocal about the need to improve efficiencies in the healthcare system and to put a lid on the spiralling cost of care.

    With federal reviews into private health insurance and the Medicare Benefits Schedule, among other parts of the health system, there could be significant changes in fortune for the insurers who pay medical bills.

    Throughout 2015, NIB shares have been volatile after rising to nearly $3.90 in March before falling to a low of $3 in October.

    However, consistent profit and dividend growth has been a regular feature from NIB in recent years helping the company’s share price lift 10% for FY 15/16.

    VIEW ARTICLE

Exceptional Performance

Nov 2014 - Nov 2016

Our short-term focused Trading Report returned 30.03%, outperforming the ASX/200 Accumulation Index by 23.58%*

View Latest Recommendations
ASR
Aussie 200

DISCLAIMER:
*Performance is derived from recommendations provided by Australian Stock Report’s Trading Report, opened on or after date of acquisition in Nov 2014
*Return figures are gross returns and do not take into account fees or brokerage costs.
*Returns are calculated based on a $50,000 hypothetical portfolio, risking 2% of the overall portfolio balance ($1,000) as a starting point for each trade.
*Due to slippage and gapping, losses can sometimes exceed $1,000 on an individual trade.
*Opening and closing prices for trades (and therefore the prices used for determining aggregate profit/loss) will be those published on the Australian Stock Report website and will be determined by the price at which they could realistically be executed in the market at the time the recommendation is published.
*ASX 200 Accumulation Index Return is calculated based upon the price of the index at the start of the session on the day the first ASX 200 trade was placed, i.e. 24.11.2015

Start your 7 day FREE trial and get
access to our premium reports!

We’re here to help

Need to speak to someone about companies or investing?
Our knowledgeable team is on hand to assist